New Chief Scientific Officer has started
Tessellate Bio (Naarden, Netherlands; Stevenage, UK) appointed Dr Katie Chapman as Chief Scientific Officer (CSO) at the end of September. She succeeds Dr Jürgen Moll, who will be available to the company in an advisory capacity.
Precision oncology company Tessellate Bio (Naarden, NL; Stevenage, UK) appointed Dr Katie Chapman as Chief Scientific Officer (CSO) at the end of September. She succeeds Dr Jürgen Moll, who is taking on a new professional challenge. However, he will continue to be available to the company as a consultant.
Since joining Tessellate Bio in 2022, Chapman has already played a key role in advancing the company’s pipeline and programmes.
Prior to her move, the in vitro pharmacologist served as Head of Discovery Biology. Chapman has held senior positions at MSD and Domainex, among others, and was an Honorary Research Fellow at Imperial College London. She began her pharmaceutical career at GSK and received her PhD from the University of Leeds, UK, on the structure and function of GPCRs.
NATO
Die Hoffotografen GmbH
GSK